loading

It is a long established fact that a reader of a page when looking at its layout.

    // Our Mission Advancing Treatments for
    Pain and Inflammation
    Advance and market novel patent-protected treatments for
    chronic inflammatory diseases - such as Sickle Cell Disease,
    Osteoarthritis, cancer and dementias - through transdermal
    drug loading of circulating blood cells for targeted
    delivery within the vasculature.
    Learn More
    Innovating treatments for chronic diseases via transdermal loading of drugs into circulating blood cells for targeted anti-inflammatory activity

    Vascarta is a clinical-stage pharmaceutical company built on three core assets designed to increase therapeutic effectiveness while improving the patient experience.
    Leading areas of study are Sickle Cell disease, Osteoarthritis, Dementia, and Cancer.

    Vasporta™ Transdermal Delivery

    A patented topical system that enhances absorption, bypasses oral bioavailability issues, and offers a needle-free alternative to injections.
    OUR LEAD PRODUCT
    CANDIDATE: VAS-101

    Harnesses the established anti-inflammatory and pain-relieving properties of curcumin through transdermal delivery which overcomes the limited bioavailability and suboptimal effectiveness of oral dosing. Phase 1 clinical trials for Sickle Cell Disease and Osteoarthritis initiated 1Q2025 with expected completion by 4Q2025.
    Targeted
    Cancer
    Therapeutics

    Novel linker chemistry licensed from CUNY that combines curcumin with approved cancer drugs to improve efficacy and reduce side effects.
    OUR LEAD PRODUCT CANDIDATE: VAS101
    Harnesses the proven anti-inflammatory efficacy of curcumin through transdermal delivery which overcomes the limited bioavailability of oral dosing. Phase 1 clinical trials for Sickle Cell Disease and Osteoarthritis initiated 1Q2025 with expected completion by 4Q2025.
    What Sets Us Apart
    Why Vascarta? Four Pillars of Innovation
    Vasporta™ Technology:

    Advanced transdermal delivery platform designed to improve absorption, eliminate the need for injections, and overcome oral bioavailability limitations.

    Vasceptor® Formulation:
    Next-generation curcumin-based therapy demonstrating enhanced absorption, deep skin penetration, and systemic therapeutic potential through red blood cell distribution.
    Oncology Licensing Platform:
    Exclusive rights to CUNY’s novel linker chemistry, enhancing cancer drug efficacy while reducing side effects through targeted curcumin conjugation.
    Broad Therapeutic Potential:
    Applicable across multiple health areas including Sickle Cell Disease, Osteoarthritis, Hypertension, Aging, Brain Cancer, and Pancreatic Cancer.
    Proven Through Results
    Research and Clinical Trials
    fancybox
    Safety

    Extensive scientific studies confirm curcumin gel’s safety for topical application with no reported adverse effects.

    fancybox
    Pre-Clinical Validation

    Comprehensive pre-clinical studies highlight curcumin gel’s potential in addressing endothelial dysfunction.

    fancybox
    Treatments with Curcumin-Gel

    Innovative formulations show enhanced curcumin absorption, improving red blood cell health and stability.

    fancybox
    Results

    Results indicate measurable improvement in inflammation, oxidative stress, and vascular health markers.

    fancybox
    Animal Research

    Animal models demonstrate significant anti-inflammatory and wound-healing properties of curcumin gel.

    fancybox
    Other Effectiveness Studies

    Additional studies validate curcumin gel’s efficacy in diverse applications, including pain and skin repair.

    Hear From Our Founder: Revolutionizing Healthcare Through Innovation

    WHO WE ARE

    Vascarta is a clinical stage pharmaceutical company exploring the enhancement of proven medications via transdermal delivery or linker technology. Our patented technologies overcome the limitations of existing delivery systems to safely and effectively achieve therapeutic concentrations in target tissues, with fewer off-target effects. We have assembled an experienced team of industry experts in research, formulation, development committed to advancing our organization from exploration to commercialization.

    Testimonials
    What People Are Saying
    Join Us to Revolutionize Healthcare with Scalable Solutions
    pilelabs-subscribe-image
    Stay Updated on Innovation
    Subscription Form